EMA Authorised: Xofigo (radium (223Ra) dichloride) — Bayer AG

View source ↗

Summary

The EMA authorised Xofigo (radium-223 dichloride) for prostate cancer with Bayer AG as the marketing authorisation holder; decision date 28 July 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Bayer AG. Decision date: 28/07/2025